Stevanato's organic sales grew 8% in the third quarter, with adjusted EBITDA margin expanding by 200 basis points year to date. However, lower GLP-1 volumes prompted only low-single-digit sales growth guidance for fiscal 2027. Shares declined sharply by almost 27% at market open on Nov. 3.
Secular tailwinds—including the rise of biologics, peptide therapy adoption, and a shift from intravenous to subcutaneous administration—support long-term injectable demand growth.
Bears
Industrywide capacity expansion raises the risk of oversupply should biologics demand disappoint, which could trigger pricing pressure and margin compression across the packaging industry.
Stevanato Group is a provider of glass and polymer drug containment, drug delivery, and diagnostic solutions to the pharmaceutical and life sciences industries. The company operates through two segments: a Biopharmaceutical and Diagnostic Solutions segment, which offers an integrated, end-to-end portfolio of products, processes, and services spanning the full drug lifecycle; and an Engineering segment, which designs, develops, and manufactures advanced machinery for pharmaceutical manufacturing, covering visual inspection, assembly and packaging, glass converting, and serialization. Stevanato's revenue is geographically diversified, with approximately 60% of sales generated in Europe, the Middle East, and Africa, 30% in North America, 8% in Asia-Pacific, and 2% in South America.